Identification of Isoform 2 Acid-Sensing Ion Channel Inhibitors as Tool Compounds for Target Validation Studies in CNS.
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
11 Apr 2019
11 Apr 2019
Historique:
received:
30
11
2018
accepted:
07
02
2019
entrez:
19
4
2019
pubmed:
19
4
2019
medline:
19
4
2019
Statut:
epublish
Résumé
Acid-sensing ion channels (ASICs) are a family of ion channels permeable to cations and largely responsible for the onset of acid-evoked ion currents both in neurons and in different types of cancer cells, thus representing a potential target for drug discovery. Owing to the limited attention ASIC2 has received so far, an exploratory program was initiated to identify ASIC2 inhibitors using diminazene, a known
Identifiants
pubmed: 30996808
doi: 10.1021/acsmedchemlett.8b00591
pmc: PMC6466820
doi:
Types de publication
Journal Article
Langues
eng
Pagination
627-632Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Physiol Rev. 2003 Oct;83(4):1183-221
pubmed: 14506304
Nat Biotechnol. 2006 Apr;24(4):439-46
pubmed: 16550174
J Biol Chem. 2006 Jul 14;281(28):19220-32
pubmed: 16704974
J Neurochem. 2008 Jul;106(1):429-41
pubmed: 18410516
Neuropharmacology. 2010 Jun;58(7):1045-53
pubmed: 20114056
Eur J Pharmacol. 2010 Dec 1;648(1-3):15-23
pubmed: 20854810
Am J Physiol Cell Physiol. 2012 Apr 1;302(7):C943-65
pubmed: 22277752
ACS Chem Neurosci. 2011 Jan 19;2(1):26-37
pubmed: 22778854
Nat Rev Neurosci. 2013 Jul;14(7):461-71
pubmed: 23783197
BMB Rep. 2013 Jun;46(6):295-304
pubmed: 23790972
Mol Biosyst. 2014 Oct;10(10):2724-34
pubmed: 25096593
Pharmacol Rev. 2015;67(1):1-35
pubmed: 25287517
Neuropharmacology. 2015 Jul;94:19-35
pubmed: 25613302
J Biomol Screen. 2016 Apr;21(4):372-80
pubmed: 26597957
Mol Brain. 2016 Jan 08;9:4
pubmed: 26746198
Br J Pharmacol. 2016 Sep;173(18):2671-701
pubmed: 27278329
J Cancer. 2016 Sep 13;7(13):1888-1891
pubmed: 27698929
Sci Rep. 2017 Mar 21;7:44843
pubmed: 28322303
J Exp Clin Cancer Res. 2017 Sep 19;36(1):130
pubmed: 28927426
Mol Pharmacol. 2017 Dec;92(6):665-675
pubmed: 29025967
Sci Rep. 2018 May 8;8(1):7179
pubmed: 29739981
PLoS One. 2018 May 21;13(5):e0196894
pubmed: 29782492